MUMBAI (Reuters) - India's foreign exchange and debt markets are closed on Wednesday for a holiday but equity markets will remain open.
Trading of Nifty 50 index futures on the Singapore stock exchange indicates that the Nifty could fall 10 points at the opening bell.
Dr. Reddy's Laboratories announced favorable outcome in Buprenorphine and Naloxone Sublingual Film patent litigation. The United States Court of Appeals for the Federal Circuit issued a decision in favor of Dr. Reddy's Laboratories Inc., concluding that lndivior had not shown that it is likely to succeed on the merits of its infringement case on US Patent No. 9,931,305. This decision vacates the District Court's preliminary injunction that had prohibited Dr. Reddy's from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. As a result of the ruling, Dr. Reddy's will resume its launch activities as soon as permitted. The announcement was made after market hours yesterday, 20 November 2018.
Sales rise 15.13% to Rs 2.74 crore
Sales decline 82.65% to Rs 1.31 crore
Sales decline 55.48% to Rs 1.38 crore
Sales rise 12.72% to Rs 11.34 crore
Sales rise 14.22% to Rs 19.12 crore
Sales rise 583.53% to Rs 17.43 crore
Sales decline 80.70% to Rs 10.02 crore
Sales rise 47.22% to Rs 1.06 crore
Sales rise 1140.00% to Rs 0.62 crore
Sales rise 14.29% to Rs 0.08 crore
Sales decline 43.95% to Rs 27.97 crore
Sales rise 15.02% to Rs 10.34 crore